Pharmaron Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
20,342
- Stock Symbol
-
300759
- Investments
-
15
- Share Price
-
$3.83
- (As of Friday Closing)
Pharmaron General Information
Description
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Contact Information
Website
www.pharmaron.comCorporate Office
- 6 Taihe Road
- BDA
- Beijing, 100176
- China
Corporate Office
- 6 Taihe Road
- BDA
- Beijing, 100176
- China
Pharmaron Stock Performance
As of 14-Mar-2025, Pharmaron’s stock price is $3.83. Its current market cap is $6.3B with 1.78B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.83 | $3.64 | $2.44 - $5.19 | $6.3B | 1.78B | 20.9M | $0.15 |
Pharmaron Financials Summary
As of 30-Sep-2024, Pharmaron has a trailing 12-month revenue of $1.64B.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 7,520,490 | 7,217,472 | 11,498,086 | 16,596,580 |
| Revenue | 1,643,197 | 1,630,840 | 1,524,423 | 1,152,807 |
| EBITDA | 320,819 | 411,838 | 370,429 | 375,957 |
| Net Income | 262,445 | 226,307 | 204,113 | 257,241 |
| Total Assets | 3,361,243 | 3,735,112 | 2,970,237 | 2,884,976 |
| Total Debt | 832,765 | 1,368,054 | 886,542 | 829,155 |
Pharmaron Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pharmaron Comparisons
Industry
Financing
Details
Pharmaron Competitors (35)
One of Pharmaron’s 35 competitors is Syngene International, a Formerly PE-Backed company based in Bangalore, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Syngene International | Formerly PE-Backed | Bangalore, India | ||||
| Pharmaceutical Product Development | Formerly PE-Backed | Waltham, MA | ||||
| Aragen Life Sciences | Private Equity-Backed | Hyderabad, India | ||||
| Shanghai Medicilon | Formerly VC-backed | Shanghai, China | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany |
Pharmaron Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pharmaron Patents
Pharmaron Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250034129-A1 | Crystalline forms of (6s,7s)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2h-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione | Pending | 28-Jul-2023 | ||
| US-20250000856-A1 | Crystalline forms of n-((1r,3s)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1h-indole-2-carboxamide | Pending | 18-Nov-2021 | ||
| US-20220281893-A1 | Tetracyclic oxazepine compounds and uses thereof | Inactive | 09-Feb-2021 | ||
| CA-3199345-A1 | Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same | Pending | 10-Nov-2020 | ||
| AU-2020477113-A1 | Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same | Pending | 10-Nov-2020 | C07F9/65583 |
Pharmaron Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pharmaron Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pharmaron Investments & Acquisitions (15)
Pharmaron’s most recent deal was a Corporate Asset Purchase with Noramco (API Manufacturing Site in Coventry). The deal was made on 12-Jul-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Noramco (API Manufacturing Site in Coventry) | 12-Jul-2022 | Corporate Asset Purchase | Buildings and Property | ||
| Aesica Pharmaceuticals | 07-Jan-2022 | Merger/Acquisition | Pharmaceuticals | ||
| Pharmaron Biologics | 30-Apr-2021 | Merger/Acquisition | Clinics/Outpatient Services | ||
| Imago BioSciences | 19-Nov-2020 | Later Stage VC | Drug Discovery | ||
| Absorption Systems | 08-Nov-2020 | Merger/Acquisition | Biotechnology |
Pharmaron ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
14.46 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 60
Rank
Percentile
Pharmaron Exits (5)
Pharmaron’s most recent exit was on 19-Nov-2020 from Imago BioSciences. The exit was categorized as with 14 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Imago BioSciences | 19-Nov-2020 | Completed |
|
||
| Zentalis Pharmaceuticals | 09-Dec-2019 | Completed |
|
||
| Imago BioSciences | 15-Mar-2019 | Completed |
|
||
| Zentalis Pharmaceuticals | 01-Jan-2017 | Completed |
|
||
| Zentalis Pharmaceuticals | 14-Mar-2016 | Early Stage VC | Completed |
|
Pharmaron Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Bayland Capital | Beijing, China | 2019 | |
| Quotient Bioresearch | Fordham, United Kingdom | 1940 |
Pharmaron FAQs
-
When was Pharmaron founded?
Pharmaron was founded in 2004.
-
Where is Pharmaron headquartered?
Pharmaron is headquartered in Beijing, China.
-
What is the size of Pharmaron?
Pharmaron has 20,342 total employees.
-
What industry is Pharmaron in?
Pharmaron’s primary industry is Pharmaceuticals.
-
Is Pharmaron a private or public company?
Pharmaron is a Public company.
-
What is Pharmaron’s stock symbol?
The ticker symbol for Pharmaron is 300759.
-
What is the current stock price of Pharmaron?
As of 14-Mar-2025 the stock price of Pharmaron is $3.83.
-
What is the current market cap of Pharmaron?
The current market capitalization of Pharmaron is $6.3B.
-
What is Pharmaron’s current revenue?
The trailing twelve month revenue for Pharmaron is $1.64B.
-
Who are Pharmaron’s competitors?
Syngene International, Pharmaceutical Product Development, Aragen Life Sciences, Shanghai Medicilon, and Evotec are some of the 35 competitors of Pharmaron.
-
What is Pharmaron’s annual earnings per share (EPS)?
Pharmaron’s EPS for 12 months was $0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
